Merck: The Worst Has Been Avoided (Rating Upgrade)
Summary: On April 25, one of the leaders in the global oncology drugs market published
Summary: On April 25, one of the leaders in the global oncology drugs market published
Summary: Three months have passed since I initiated coverage of Merck stock, during which time
Summary: Merck is set to announce its Q1 2024 earnings next week, with analysts predicting
Summary: We have been overly cautious in our previous articles, as MRK runs away to
Summary: After a forgettable last year, Merck & Co., Inc.’s stock price is up 20%
Summary: Merck’s FDA approval of Winrevair for PAH treatment follows its $11 billion acquisition of
Summary: Merck has crushed the market since I last covered it in December. The pharmaceutical’s
Summary: Merck’s strong performance in 2023, driven by key products like KEYTRUDA, demonstrates resilience despite
Summary: Merck & Co has experienced significant share price growth across the past 3 years,
Summary: Merck & Co. is likely to positively surprise the market on February 1, 2024